Takeda's narcolepsy drug meets phase 3 trial goals

Takeda Pharmaceutical announced oveporexton met all primary and secondary endpoints in two pivotal phase 3 studies across 19 countries for narcolepsy type 1.

The drug showed statistically significant improvements in wakefulness, excessive daytime sleepiness, and cataplexy with no serious treatment-related adverse events. Takeda plans to submit a new drug application in fiscal year 2025.